MedTrace Logo

Assessment of Drug Liking In Peri-procedural Clinical Settings

NCT07015528 · Status: ENROLLING_BY_INVITATION · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2026-05-08

No results posted yet for this study

Summary

The purpose of this study is to evaluate whether medications used in peri-procedural clinical settings can modulate drug liking.

Conditions

  • Drug Liking

Interventions

DRUG

Droperidol

Medication administered as a single intravenous dose.

DRUG

Placebo

Matching Placebo given by single intravenous (IV) administration.

Sponsors & Collaborators

Principal Investigators

  • Patrick L Purdon, PhD · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-30
Primary Completion
2026-08-31
Completion
2027-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07015528 on ClinicalTrials.gov